HC Wainwright Comments on Surrozen FY2026 Earnings

Surrozen, Inc. (NASDAQ:SRZN – Free Report) – Stock analysts at HC Wainwright issued their FY2026 earnings per share estimates for Surrozen in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst M. Caufield expects that the company will earn ($12.01) per share for the year. HC Wainwright has a “Buy” rating and a $54.00 price objective on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($10.89) per share. HC Wainwright also issued estimates for Surrozen’s Q4 2026 earnings at ($1.40) EPS, FY2027 earnings at ($5.19) EPS, FY2028 earnings at ($5.46) EPS, FY2029 earnings at ($5.64) EPS and FY2030 earnings at ($5.35) EPS.

A number of other equities research analysts have also recently commented on the stock. Wall Street Zen cut shares of Surrozen from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, October 15th. William Blair assumed coverage on shares of Surrozen in a report on Thursday, August 20th. They issued an “outperform” rating and a $51.00 price target on the stock. Guggenheim set a $80.00 price target on shares of Surrozen and gave the company a “buy” rating in a report on Wednesday. Finally, Zacks Research upgraded shares of Surrozen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $61.75.

Check Out Our Latest Stock Analysis on Surrozen

Surrozen Stock Down 0.2%

Surrozen stock opened at $31.61 on Thursday. Surrozen has a 52 week low of $12.31 and a 52 week high of $37.83. The firm’s 50-day simple moving average is $25.90 and its 200 day simple moving average is $25.52. The firm has a market capitalization of $366.99 million, a PE ratio of -0.73 and a beta of 0.51.

Surrozen (NASDAQ:SRZN – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($11.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($9.92).

Hedge Funds Weigh In On Surrozen

A number of institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC purchased a new stake in shares of Surrozen in the first quarter valued at $6,682,000. Renaissance Technologies LLC boosted its stake in shares of Surrozen by 117.1% during the first quarter. Renaissance Technologies LLC now owns 49,126 shares of the company’s stock valued at $1,431,000 after acquiring an additional 26,500 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Surrozen during the 2nd quarter worth about $399,000. ADAR1 Capital Management LLC purchased a new stake in Surrozen during the 1st quarter worth about $350,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Surrozen by 37.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,000 shares of the company’s stock worth $160,000 after purchasing an additional 1,350 shares in the last quarter. 66.57% of the stock is owned by institutional investors and hedge funds.

Surrozen News Summary

These are some of the SRZN news items that stood out recently:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $54 price target, signaling potential upside in the analyst’s view despite reduced earnings forecasts. HC Wainwright estimates and rating
  • Negative Sentiment: Surrozen priced an underwritten offering of 1,894,540 common shares at $31.67 each, raising about $60 million before expenses. The new shares dilute existing shareholders and could weigh on the stock, while providing additional funding for the company. Surrozen announces offering pricing
  • Negative Sentiment: HC Wainwright lowered its projected earnings per share across several future years, including estimates of losses of $12.01 for 2026 and $5.19 for 2027. The lower forecasts underscore continued expected losses, despite the firm’s Buy rating. HC Wainwright earnings estimates

Surrozen Company Profile

(Get Free Report)

Surrozen, Inc. is a biotechnology company developing antibody-based medicines designed to activate the Wnt signaling pathway, which plays a role in tissue growth and repair. The company uses its proprietary platform to develop therapies intended to stimulate regeneration in specific tissues while limiting effects elsewhere in the body. Surrozen’s research has included candidates aimed at liver disease and inflammatory bowel disease, including SZN-043 and SZN-1326. Its work focuses on advancing potential treatments through research and clinical development; the company’s products are investigational and are not approved medicines.

Featured Articles

Earnings History and Estimates for Surrozen (NASDAQ:SRZN)

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.